Kyung Hee University Medical Center Reports Findings in Prostatic Hyperplasia (Drug Prescription Patterns During Initial Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Study Based on Health Insurance …): Urogenital Diseases and Conditions – Prostatic Hyperplasia

2022 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Urogenital Diseases and Conditions - Prostatic Hyperplasia is the subject of a report. According to news reporting from Seoul, South Korea, by NewsRx journalists, research stated, “To evaluate the drug prescription patterns for men diagnosed with benign prostatic hyperplasia (BPH) in Korea. We extracted the data of 3% of the national patient samples including men aged 40 years between 2012 and 2017 from the Health Insurance Review and Assessment database and investigated the drugs prescribed for men with the BPH code N40.”

Financial support for this research came from Soonchunhyang University.

The news correspondents obtained a quote from the research from Kyung Hee University Medical Center, “Men with a diagnosis of BPH but not receiving treatment were excluded. The primary outcome was the drugs prescribed and the changes in drug prescription pattern over 6 years for men first diagnosed with BPH. Alpha blockers were the most commonly prescribed drugs in men with BPH, and tamsulosin was the most common. The proportion of prescriptions increased steadily. The number of prescriptions for anticholinergics (ACH) increased, but decreased with the start of mirabegron prescriptions in 2015. Prescriptions of mirabegron are increasing rapidly and replacing ACH. Based on the prescription pattern by drug category, alpha blocker monotherapy decreased, whereas combination therapies such as alpha blocker + 5-alpha-reductase inhibitors (5ARI), and alpha blocker + 5ARI + ACH increased steadily. As for the number of prescriptions by drug ingredient, tamsulosin monotherapy was the most common, and the combination therapy of tamsulosin and mirabegron increased. Alpha blockers were the most commonly prescribed drug for men first diagnosed with BPH in Korea from 2012 to 2017, and tamsulosin was the most common alpha blocker.”

According to the news reporters, the research concluded: “Prescriptions of combination therapy and mirabegron are gradually increasing.”

For more information on this research see: Drug Prescription Patterns During Initial Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Study Based on Health Insurance Review and Assessment Database. Journal of Korean Medical Science, 2022;37(12). Journal of Korean Medical Science can be contacted at: Korean Acad Medical Sciences, 302 75 Dong Du Ichon, Dong Yongsan Ku, Seoul 140 031, South Korea.

Our news journalists report that additional information may be obtained by contacting Jeong Woo Lee, Dept. of Urology, Kyung Hee University, Kyung Hee University College of Medicine, Seoul, South Korea.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3346/jkms.2022.37.e95. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the Journal of Korean Medical Science is: Korean Acad Medical Sciences, 302 75 Dong Du Ichon, Dong Yongsan Ku, Seoul 140 031, South Korea.

(Our reports deliver fact-based news of research and discoveries from around the world.)